PAPER Chung SJ, Kim MJ, Kim YJ, Kim J, You S, Jang EH, Kim SY, Lee JH
SEARCH RESULTS
331119 RESULTS
PAPER Anderkova L, Rektorova I
Cognitive effects of repetitive transcranial magnetic stimulation in patients with neurodegenerative diseases- clinician's perspective.
J Neurol Sci. 2014 Apr 15;339(1-2):15-25. Epub 2014 Feb 4 PubMed: 24530170PAPER Wang X, Zhu M, Hjorth E, Cortés-Toro V, Eyjolfsdottir H, Graff C, Nennesmo I, Palmblad J, Eriksdotter M, Sambamurti K, Fitzgerald JM, Serhan CN, Granholm AC, Schultzberg M
Resolution of inflammation is altered in Alzheimer's disease.
Alzheimers Dement. 2014 Feb 12; PubMed: 24530025PAPER Mirza SS, de Bruijn RF, Direk N, Hofman A, Koudstaal PJ, Ikram MA, Tiemeier H
Depressive symptoms predict incident dementia during short- but not long-term follow-up period.
Alzheimers Dement. 2014 Feb 12; PubMed: 24530024PAPER Ferreira ST, Clarke JR, Bomfim TR, De Felice FG
Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease.
Alzheimers Dement. 2014 Feb;10(1 Suppl):S76-83. PubMed: 24529528PAPER Greig NH, Tweedie D, Rachmany L, Li Y, Rubovitch V, Schreiber S, Chiang YH, Hoffer BJ, Miller J, Lahiri DK, Sambamurti K, Becker RE, Pick CG
Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury.
Alzheimers Dement. 2014 Feb;10(1 Suppl):S62-75. PubMed: 24529527PAPER Femminella GD, Edison P
Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging.
Alzheimers Dement. 2014 Feb;10(1 Suppl):S55-61. PubMed: 24529526PAPER Hölscher C
The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease.
Alzheimers Dement. 2014 Feb;10(1 Suppl):S47-54. PubMed: 24529525PAPER Foltynie T, Aviles-Olmos I
Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic.
Alzheimers Dement. 2014 Feb;10(1 Suppl):S38-46. PubMed: 24529524PAPER Hölscher C
First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease.
Alzheimers Dement. 2014 Feb;10(1 Suppl):S33-7. PubMed: 24529523PAPER Steculorum SM, Solas M, Brüning JC
The paradox of neuronal insulin action and resistance in the development of aging-associated diseases.
Alzheimers Dement. 2014 Feb;10(1 Suppl):S3-11. PubMed: 24529522PAPER De Felice FG, Lourenco MV, Ferreira ST
How does brain insulin resistance develop in Alzheimer's disease?
Alzheimers Dement. 2014 Feb;10(1 Suppl):S26-32. PubMed: 24529521PAPER Talbot K, Wang HY
The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.
Alzheimers Dement. 2014 Feb;10(1 Suppl):S12-25. PubMed: 24529520PAPER Bamne MN, Demirci FY, Berman S, Snitz BE, Rosenthal SL, Wang X, Lopez OL, Kamboh MI
Investigation of an amyloid precursor protein protective mutation (A673T) in a North American case-control sample of late-onset Alzheimer's disease.
Neurobiol Aging. 2014 Jul;35(7):1779.e15-6. Epub 2014 Jan 23 PubMed: 24529499PAPER Guerrero-Berroa E, Schmeidler J, Beeri MS